DENVER, Aug. 10, 2012 /PRNewswire/ -- Accelr8 Technology Corp. (NYSE MKT: AXK) today announced that it has named Steve Reichling as Chief Financial Officer.
Reichling joins Accelr8 from Roche Tissue Diagnostics where he served as general manager of its antibody R&D and research products subsidiary, Spring Bioscience Corp. Prior to this role he held various finance, accounting and operations leadership roles at Roche Tissue Diagnostics and Ventana Medical Systems including director of finance and operations, manager of business development finance, and head of Internal Audit and Sarbanes Oxley Compliance. Prior to his tenure at Roche Tissue Diagnostics and Ventana Medical Systems, Reichling was a life sciences company auditor at Ernst & Young LLP. He holds a B.A. in accounting and entrepreneurship from the University of Arizona and is a Certified Public Accountant.
"We are delighted to welcome Steve to the Accelr8 leadership team," said John Patience, Accelr8's Chairman of the Board. "Steve's finance and accounting expertise and broad business skill set will be invaluable in helping us realize the potential of Accelr8's technologies."
"I am excited to be joining such a promising diagnostics company at this important time in its development," said Reichling. "Accelr8 promises to deliver substantial improvements to patient care and I am looking forward to working with the team to bring this revolutionary technology to market."
Accelr8 Technology Corp. (www.accelr8.com) is a developer of innovative materials and instrumentation for advanced applications in medical instrumentation, basic research, drug discovery, and bio-detection. Accelr8 is developing a rapid analytical platform for infectious pathogens, the BACcel system, based on its innovative assay processing and detection technologies. In addition, Accelr8 licenses certain of its proprietary technology for use in applications outside of Accelr8's own products.
Certain statements in this news release may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements regarding future prospects and developments are based upon current expectations and involve certain risks and uncertainties that could cause actual results and developments to differ materially from the forward-looking statement, including those detailed in the company's filings with the Securities and Exchange Commission. Accelr8 does not undertake an obligation to publicly update or revise any forward-looking statements, whether as a result of new information or future events.
SOURCE Accelr8 Technology Corp.